User:David J Dowling/sandbox

David J. Dowling
David James Dowling is currently an Assistant Professor of Pediatrics at Harvard Medical School (HMS) and faculty at Boston Children's Hospital (BCH).

Education and career
Dowling grew up in Bray, County Wicklow, Ireland and earned his B.S. in Biotechnology from Dublin City University (DCU) in 2005. He continued his studies at the Dublin City University (DCU), where in 2009, he earned Ph.D. in Immunology, Vaccinology and Parasitology in the laboratory of Sandra O’Neill. After receiving his Ph.D., Dowling completed a postdoctoral fellowship at Harvard Medical School (HMS) from 2010 to 2017. In 2018, Dowling was promoted to Principal Investigator/Faculty at Boston Children's Hospital (BCH), and Instructor of Pediatrics, at Harvard Medical School (HMS). Moving his laboratory to the newly established Precision Vaccine Program at BCH, he was promoted to Assistant Professor of Pediatrics at Harvard Medical School (HMS) in 2024.

Vaccine Development
Dowing is best known for his focus on precision adjuvant science and elucidation of mechanistic immune responses in age- and population-specific manners.

COVID-19 pandemic response.
Dowling contributed to the development of Corbevax, an adjuvanted protein subunit COVID-19 vaccine. Researchers at Precision Vaccine Program at Boston Children's Hospital and Harvard Medical School, in Boston, MA, in collaboration with Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas, undertook an exhaustive screening process that compared multiple molecules head-to-head in different combinations. Two adjuvants — aluminum hydroxide and CpG—proved to be the most successful combination when added to the RBD protein, especially in models of older populations.

Opioid epidemic response.
Dowling is a co-founder of OVAX Inc, a company focused on Fentanyl Overdose Vaccine development.